非转移性去势抵抗性前列腺癌中雄激素剥夺治疗与雄激素受体抑制剂的骨健康影响
本文综述非转移性去势抵抗性前列腺癌(nmCRPC)患者接受雄激素剥夺治疗及新型雄激素受体抑制剂(ARI)对骨健康的影响。通过PubMed检索2000年至今文献,讨论骨脆性风险因素及3期试验中三种ARI的骨相关数据,并提出骨密度评估、营养指导及抗骨吸收药物等管理策略。
要点
- nmCRPC患者因高龄、性腺功能减退和长期ADT存在骨脆性风险。
- 新型ARI在少量患者中与跌倒或骨折相关。
- 管理应包括定期骨密度评估、营养指导及必要时抗骨吸收药物。
核心结论
- 在nmCRPC患者中,衰老和抗雄激素治疗导致骨脆性,新型ARI在少量患者中与跌倒或骨折相关。
- 管理指南包括定期评估骨密度、营养指导及必要时使用抗骨吸收药物。
研究设计与样本
- 综述:检索PubMed数据库2000年至今的同行评议文献,关键词包括「androgen-deprivation therapy」「androgen receptor inhibitors」「bone」「bone complications」「nonmetastatic prostate cancer」。
主要发现
- nmCRPC患者接受新型ARI可能出现骨密度下降。
- 3期试验数据显示三种已获批ARI对骨的影响在少量患者中与跌倒或骨折相关。
临床怎么用
- 对接受ARI治疗的nmCRPC患者应定期评估骨密度。
- 提供营养指导,并在有指征时使用抗骨吸收药物。
局限性
- 原文未明确报告综述的纳入研究数量或偏倚评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy. Despite absence of metastatic disease, patients with nonmetastatic castrate-resistant prostate cancer receiving newer androgen receptor inhibitors can experience decreased bone mineral density. A systematic approach to bone health care has been hampered by a simplistic view that does not account for heterogeneity among prostate cancer patients or treatments they receive. This review aims to raise awareness in oncology and urology communities regarding the complexity of bone health, and to provide a framework for management strategies for patients with nonmetastatic castrate-resistant prostate cancer receiving androgen receptor inhibitor treatment. METHODS: We searched peer-reviewed literature on the PubMed database using key words "androgen-deprivation therapy," "androgen receptor inhibitors," "bone," "bone complications," and "nonmetastatic prostate cancer" from 2000 to present. RESULTS: We discuss how androgen inhibition affects bone health in patients with nonmetastatic castrate-resistant prostate cancer. We present data from phase 3 trials on the three approved androgen receptor inhibitors with regard to effects on bone. Finally, we present management strategies for maintenance of bone health. CONCLUSIONS: In patients with nonmetastatic castrate-resistant prostate cancer, aging, and antiandrogen therapy contribute to bone fragility. Newer androgen receptor inhibitors were associated with falls or fractures in a small subset of patients. Management guidelines include regular assessment of bone density, nutritional guidance, and use of antiresorptive bone health agents when warranted.
引用
- Hussain A, Tripathi A, Pieczonka C, et al. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 33028943. doi:10.1038/s41391-020-00296-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。